# **LUPUS NEPHRITIS and PREGNANCY**

### Zahra Shafii, MD.

### **Assistant Professor of Nephrology**


Shaheed Rajaie Cardiovascular Medical and Research Institute

# Introduction

Lupus nephritis (LN) :


- severe manifestation of SLE
- Prevalence rates in SLE patients : 20% to 65%
- associated with higher mortality
- Pregnant women with LN are at increased risk for complications

### Kidney Changes During Pregnancy



Serum Cr: 10- 20% drop GFR:~505 increase

### **Pregnancy Immunological Changes**




## Normal Pregnancy Immunological Changes

- Increase in CD41/CD251 regulatory T cells (Tregs)
- Shift from Th1 (proinflammatory) mediated to Th2 (antiinflammatory) antibody-mediated response.
- This Th1 to Th2 shift can increase the activity of Th2-mediated diseases like SLE
- Hormonal changes affect lupus activity: estrogen accelerates glomerulonephritis, lymphoproliferation, and mortality

# **New EULAR/ACR criteria for the classification of SLE**

Clinical domains	Points	Immunologic domains	Points
<i>Constitutional domain</i> Fever	2	Antiphospholipid antibody domain Anticardiolipin IgG > 40 GPL	2
Cutaneous domain Non-scarring alopecia Oral ulcers Subacute cutaneous or discoid lupus Acute cutaneous lupus	2	<i>or</i> anti-β2GP1 lgG > 40 units <i>or</i> lupus anticoagulant	
	4 6	Complement proteins domain Low C3 or low C4	3
Arthritis domain Synovitis or tenderness in at least 2 joints	6	Low C3 and low C4 Highly specific antibodies domain	4
<i>Neurologic domain</i> Delirium Psychosis Seizure	2 3 5	Anti-dsDNA antibody Anti-Sm antibody	6 6
Serositis domain Pleural or pericardial effusion Acute pericarditis		REFERENCE: Aringer et al. Abstract #2928. 2018 ACR/ARHP Annual M	Veeting
	5 6	<ul> <li>✓ Classification criteria are not diagnosis criteria</li> <li>✓ All patients classified as having SLE must have ANA ≥ 1:80 (entry criterion)</li> </ul>	
Hematologic domain Leukopenia Thrombocytopenia Autoimmune hemolysis	3	✓ Patients must have ≥ 10 points to be classified as SLE	
	4 4	$\checkmark$ Items can only be counted for classification if there is no more likely cause	
<b>Renal domain</b> Proteinuria > 0.5 g/24 hr Class II or V lupus nephritis		✓ Only the highest criterion in a given domain counts	
	4	<ul> <li>SLE classification requires points from at least one clinical domain</li> </ul>	
Class III or IV lupus nephritis	10	@Lupusret	ference



# FERTILITY

- No direct impact
- Both treatment (eg, cyclophosphamide) and consequences (eg, advanced chronic kidney disease) decrease fertility.
- cyclophosphamide Premature ovarian failure: 12%-39% in various studies
- Higher IN:

total cumulative dose women over age 31 at the time of treatment after oral administration

# Pregnancy Risks for LN patients

LN Flare

# Mother


Pre-eclampsia Placenta abruptio C-section Deterioration of kidney function



Failure of pregnancy Pre-term delivery Small for gestational age Drug complication

# What are the maternal outcomes in women with stable lupus nephritis?





**Conclusion:** In pregnant women with lupus nephritis adverse maternal outcomes were relatively common but proved to be reversible when promptly diagnosed and treated. Immunological activity, arterial hypertension and BMI may predispose to maternal complications **References:** Moroni et al. *Maternal outcome in pregnant women with lupus nephritis – A prospective multicenter study.* 2016. 10.1016/j.jaut.2016.06.012.


Visual abstract by Krithika Mohan MD DNB


😏 @krithicism

### POOR OUTCOME RISK FACTORS

- Active disease
- Recent AKI
- Presence of SS-A and SS-B
- Presence of antiphospholipid antibody
- On pregnancy-incompatible medication
- BP control & level of proteinuria
- Creatinine level

### **Risk Stratification**





# Management of Lupus Nephritis (LN) in Pregnancy

- Severe Organ Impairment (Group 3):
  - High risk of disease progression and pregnancy complications (e.g., heart failure, kidney disease). Consider alternatives like adoption or surrogacy.
- Active LN (Group 2):
- Wait 6 months after remission before pregnancy

### • Stable LN in Remission (Group 1):

- Optimal time for pregnancy.
- Discontinue teratogenic medications 3 months prior, switch to safe alternatives (azathioprine, calcineurin inhibitors).
- Monitor kidney function, blood pressure, and proteinuria.

### General Recommendations:

- Hydroxychloroquine (HCQ): Safe in pregnancy, reduces flare risk, slight increased risk of congenital malformations at high doses.
- Low-dose Aspirin & Calcium: Prevent preeclampsia.
- **Multidisciplinary Care:** Regular maternal & fetal monitoring, including ultrasounds and kidney function tests.

### Contraception


#### •Preferred Methods:

#### Intrauterine Device (IUD):

- •Copper IUD safe for most LN patients.
- •Levonorgestrel-based IUD is an option if benefits outweigh thrombotic risks.

#### •Progestin-Only Contraception (POC):

- •Options include pills, depot injections, or subdermal implants.
- •Suitable for those with positive APS antibodies or thrombotic risks.
- Lower thromboembolism risk compared to estrogen-based options **Avoid:**
- •Estrogen-based contraception, barrier methods, and withdrawal due to higher failure rates.



### Lupus Nephritis vs Preeclampsia

Preeclampsia		Lupus nephritis		
Clinical				
Blood pressure: hypertension	After 20 weeks of gestation	Any time during pregnancy		
Other organ affection	Occasionally CNS	Evidence of non-renal active SLE		
Laboratory investigations				
Standard blood testing				
Platelets	Low-normal	Low-normal		
Creatinine	Normal-raised	Normal to raised		
Uric acid	Elevated	Normal		
Immunology testing				
Complements	Normal-low	Low		
Anti-dsDNA	Absent or unchanged	Rising titers		
Urine testing				
Urinary sediment	Inactive (uniform pattern, reflect renal damage, no correlation with clinical course)	Active (urine sediment reflect lupus nephritis histopathology)		
24-h urine calcium	<195 mg/dl	>195 mg/dl		
Management:				
response to steroid therapy	No response	Good response		

> J Obstet Gynaecol Res. 2021 Jul;47(7):2318-2323. doi: 10.1111/jog.14815. Epub 2021 May 10.


### sFlt-1/PIGF ratio as a predictive and prognostic marker for preeclampsia

Hae Rin Jeon <sup>1</sup>, Da Hoe Jeong <sup>1</sup>, Jin Young Lee <sup>1</sup>, Eun Young Woo <sup>1</sup>, Gwi Taek Shin <sup>1</sup>, Suk-Young Kim <sup>1</sup>

> Am J Perinatol. 2021 Aug;38(S 01):e292-e298. doi: 10.1055/s-0040-1709696. Epub 2020 May 23.

#### Evaluation of the Prognostic Value of the sFlt-1/PIGF Ratio in Early-Onset Preeclampsia

Oriane Tasta <sup>1</sup>, Olivier Parant <sup>1</sup>, Safouane M Hamdi <sup>2</sup>, Mickael Allouche <sup>1</sup>, Christophe Vayssiere <sup>1</sup>, Paul Guerby <sup>1</sup> <sup>3</sup> Department of Obstetrics and Gynecology, Paule de Viguier Maternity, CHU Toulouse, Tc



# MATERNAL-FETAL MONITORING

#### **1. First Trimester:**

Ultrasound to estimate delivery date.

#### 2. Second Trimester:

Fetal anatomic survey (~18 weeks).

#### 3. Third Trimester:

- 1. Regular ultrasounds (~every 4 weeks) to evaluate fetal growth and placental sufficiency.
- 2. Increased frequency with doppler velocimetry for suspected growth restriction or placental insufficiency.

#### Fetal Monitoring (Last 4–6 Weeks):

- 1. Nonstress tests and biophysical profiles.
- 2. Customized surveillance based on maternal-fetal health assessments.

#### Anti-Ro/SSA or Anti-La/SSB Antibodies:

- 1. Risk: Neonatal lupus, congenital heart block (0.7%–2%).
- 2. Recommendations:
  - 1. Fetal echocardiography for dysrhythmia or myocarditis.
  - 2. Continuous monitoring for signs of congenital heart block.

# **Recommended Medications During Pregnancy**

### • Hydroxychloroquine (HCQ):

- Benefits:
  - Reduces lupus flares and Increases complete remission rates, especially in Class V nephritis.
  - Reduces preterm birth risk and improves neonatal outcomes.
- Safety:
  - Generally safe but doses >400 mg/day in the first trimester may increase the risk of congenital anomalies.
  - May reduce the risk of congenital heart block in at-risk fetuses.
- Low-Dose Aspirin:
- Indication: Recommended from 12 weeks gestation to reduce preeclampsia risk.
  - Helps lower preeclampsia incidence in SLE patients and improves pregnancy outcomes when combined with HCQ.

### Medications Selectively Allowed During Pregnancy

#### 1.NSAIDs:

- 1. Safe in early pregnancy but avoid beyond 30 weeks (risk of ductus arteriosus closure).
- 2. FDA advises the lowest dose between 20–30 weeks.
- 2.Glucocorticoid: Low doses (<6.5 mg/day) may still pose risks, emphasizing careful management.</p>
- **3.Azathioprine (AZA):** Compatible with pregnancy if doses are  $\leq 2 \text{ mg/kg/day}$ .
- **4.Cyclosporine:** Limited use; safe if maternal benefits outweigh fetal risks.

#### 5. Tacrolimus:

Effective for LN management; no established link to congenital anomalies.

#### **1.Antihypertensive Medications:**

Safe: Methyldopa, nifedipine, labetalol. Contraindicated: ACE inhibitors, ARBs.

### Rituximab in Pregnancy?

#### Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD

Gitanjali Das <sup>1</sup>, Vincent Damotte <sup>1</sup>, Jeffrey M Gelfand <sup>1</sup>, Carolyn Bevan <sup>1</sup>, Bruce A C Cree <sup>1</sup>, Lynn Do <sup>1</sup>, Ari J Green <sup>1</sup>, Stephen L Hauser <sup>1</sup>, Riley Bove <sup>1</sup>

> Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development

D T Klink<sup>1</sup>, R M van Elburg, M W J Schreurs, G T J van Well

Affiliations + expand -PMID: 18596903 PMCID: PMC2438602 DOI: 10.1155/2008/271363

### Medications to Use with Caution

### **Biologic Medications:**

### 1. Rituximab:

Safe before conception or in early pregnancy but avoid in the third trimester (risk of neonatal B cell depletion).

### 2. Belimumab:

Limited data but no increased risk of anomalies

# Cyclophosphamide in Pregnancy

#### Management of breast cancer during pregnancy using a standardized protocol

D L Berry <sup>1</sup>, R L Theriault, F A Holmes, V M Parisi, D J Booser, S E Singletary, A U Buzdar, G N Hortobagyi

Affiliations + expand PMID: 10071276 DOI: 10.1200/JCO.1999.17.3.855

> Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals

Alistair E Ring <sup>1</sup>, Ian E Smith, Alison Jones, Catherine Shannon, Eleni Galani, Paul A Ellis

Affiliations + expand

0

# **Contraindicated Medications in Pregnancy**

**1.Cyclophosphamide:** Avoid during the first 10 weeks of gestation; may be considered later in life-threatening scenarios.

### 2.Mycophenolate Mofetil:

Associated with congenital anomalies and first-trimester pregnancy loss. Discontinue at least 6 weeks before conception; substitute with AZA or tacrolimus.

### 3.Methotrexate:

Cease 1–3 months before conception due to fetal growth risks.

### **4.Leflunomide:**


Use cholestyramine washout before conception to eliminate residues.

### Thromboprophylaxis

Obesity (BMI >30) Age >35 Parity >= 3 Smoker Gross varicose vein Current pre-eclampsia Immobility Low-risk thrombophilia Multiple pregnancy **IVF/ART** Sub-nephrotic proteinuria



### Post Partum Period



# **Delivery and Postpartum Care**

### **Key Considerations:**

- Timing of Delivery: Based on maternal-fetal well-being
- Nephritis flare not a trigger for delivery.
- Breastfeeding:
  - Safe drugs: Hydroxychloroquine, prednisone, azathioprine, tacrolimus.
  - Unsafe drugs: Mycophenolate, methotrexate, cyclophosphamide.

### **Issues During post Partum Period**

Stop methyldopa within 2 days of delivery	
Encourage breastfeeding	
Reintroduce safe-for-breastfeeding medication	
<ul> <li>Enalapril/captopril/nifedipine/amlodipine/labetalol/atenolol</li> <li>HCQ/prednisolone/azathioprine/calcineurin inhibitor</li> </ul>	
Kidney biopsy	
Clinic follow-up	
Contraception	700

### Pregnancy Post-Kidney Transplant

- Requires stable kidney function (1-2 years post-transplant).
- Higher risks: Preeclampsia, miscarriages.
- Preparatory Steps:
  - Adjust immunosuppressants (e.g., switch from mycophenolate to azathioprine).
  - Monitor for LN recurrence, hypertension, or graft issues.

# **Renal Replacement Therapy**

#### Hemodialysis:

- Increase frequency/intensity: 5–7 sessions per week, at least 24 hours total per week.
- Target: Pre-dialysis urea levels <20 mmol/L to reduce uremic risks.

#### Anemia Management:

- Use erythropoiesisstimulating agents to maintain adequate hemoglobin levels.
- Benefits: Supports fetal growth and reduces risks of low birth weight/prematurity.


#### Nutritional Management:

- High-protein diet tailored to pregnancy and renal needs.
- Adjust vitamins/minerals (e.g., calcium, phosphate).
- Safe phosphate binders: Calcium carbonate.

#### Fluid & Electrolyte Monitoring:

• Daily adjustments to manage fluid balance and prevent complications like hypercalcemia or alkalosis

### **KIDNEY BIOPSY**




#### Kidney biopsy in pregnancy: evidence for counselling? A systematic narrative review

GB Piccoli 🔀 G Daidola, R Attini, S Parisi, F Fassio, C Naretto, MC Deagostini, N Castelluccia, M Ferraresi D Roccatello, T Todros

First published: 15 January 2013 | https://doi.org/10.1111/1471-0528.12111 | Citations: 86

Systematic review: In 197 kidney biopsies performed during gestation there were 4/197 or 2% major complication rate and 5% minor complication rate.

Do



Cristina Popa & Anoushka Krishnan, My patient with lupus wants to get pregnant- what should I know?, NSMC2022 blog PMID: 20688887, PMID: 17499705, PMID: 30772493, PMID: 32090480 Cristina Popa, MD @Nephroseeker



http://prof.rhc.ac.ir/shafii Shafii zahra@yahoo.com 021-23922013